NEXTBio Capital Management LP Makes New $5.98 Million Investment in Compass Therapeutics, Inc. $CMPX

NEXTBio Capital Management LP acquired a new position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,114,005 shares of the company’s stock, valued at approximately $5,982,000. Compass Therapeutics comprises about 3.5% of NEXTBio Capital Management LP’s portfolio, making the stock its 12th biggest position. NEXTBio Capital Management LP owned about 0.63% of Compass Therapeutics as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in CMPX. Russell Investments Group Ltd. increased its stake in Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after acquiring an additional 7,592 shares during the last quarter. Creative Planning bought a new stake in Compass Therapeutics during the second quarter worth approximately $30,000. Flagship Harbor Advisors LLC bought a new stake in Compass Therapeutics during the fourth quarter worth approximately $32,000. Strs Ohio bought a new stake in Compass Therapeutics during the first quarter worth approximately $34,000. Finally, CIBC Bancorp USA Inc. bought a new stake in Compass Therapeutics during the third quarter worth approximately $37,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Stock Performance

Shares of NASDAQ CMPX opened at $2.03 on Friday. The firm has a market capitalization of $365.58 million, a price-to-earnings ratio of -4.95 and a beta of 0.89. The stock has a 50 day moving average price of $3.17 and a 200 day moving average price of $4.76. Compass Therapeutics, Inc. has a 52-week low of $1.61 and a 52-week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). Analysts forecast that Compass Therapeutics, Inc. will post -0.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

CMPX has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Compass Therapeutics in a research note on Thursday, March 12th. Raymond James Financial cut Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Monday, April 20th. Citizens Jmp reaffirmed a “market outperform” rating and set a $10.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 28th. Finally, Wall Street Zen cut Compass Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and an average target price of $12.91.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.